Understanding how specific proteins affect tau aggregation in Alzheimer's disease
Investigating the role of Serine Arginine (SR)-Rich RNA Binding Proteins in Tau Aggregation
This study is looking at how certain proteins in our cells might affect the clumping of tau, a protein linked to Alzheimer's disease, to help us understand more about how this clumping happens and how it relates to memory loss, which could lead to new treatments for Alzheimer's.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10899529 on NIH RePORTER |
What this research studies
This research investigates the role of serine-arginine-rich RNA binding proteins in the aggregation of tau, a protein associated with Alzheimer's disease. The study aims to understand how these proteins interact with tau and potentially influence its misfolding and aggregation, which are critical processes in the progression of Alzheimer's. By employing biochemical, cellular, and in vitro assays, the research seeks to uncover the mechanisms behind tau aggregation and its relationship with cognitive decline in patients. This could lead to new therapeutic strategies targeting tau aggregation in Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline associated with tau pathology.
Not a fit: Patients with other forms of dementia not related to tau aggregation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that specifically target tau aggregation, potentially slowing the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting tau aggregation, indicating that this approach may lead to significant advancements in Alzheimer's treatment.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Shapley, Sarah — Emory University
- Study coordinator: Shapley, Sarah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.